Document Detail


Circulating plasmalogen levels and Alzheimer Disease Assessment Scale-Cognitive scores in Alzheimer patients.
MedLine Citation:
PMID:  20040248     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Plasmalogens, which are key structural phospholipids in brain membranes, are decreased in the brain and serum of patients with Alzheimer disease (AD). We performed this pilot study to evaluate the relation between the levels of circulating plasmalogens and Alzheimer Disease Assessment Scale-Cognitive (ADAS-Cog) scores in patients with AD. METHODS: We evaluated participants' ADAS-Cog scores and serum plasmalogen levels. For the 40 included AD patients with an ADAS-Cog score between 20 and 46, were tested their ADAS-Cog score 1 year later. The levels of docosahexaenoic acid plasmalogen were measured by use of liquid chromatography-tandem mass spectrometry. RESULTS: We found that the ADAS-Cog score increased significantly in AD patients with circulating plasmalogen levels that were <or= 75% of that of age-matched controls at entry into the study. There was no change in score among participants with normal serum plasmalogen levels at baseline (> 75%). LIMITATIONS: This was a pilot study with 40 patients, and the results require validation in a larger population. CONCLUSION: Our study demonstrates that decreased levels of plasmalogen precursors in the central nervous system correlate with functional decline (as measured by ADAS-Cog scores) in AD patients. The use of both ADAS-Cog and serum plasmalogen data may be a more accurate way of predicting cognitive decline in AD patients, and may be used to decrease the risk of including patients with no cognitive decline in the placebo arm of a drug trial.
Authors:
Paul L Wood; Rishikesh Mankidy; Shawn Ritchie; Doug Heath; Julie A Wood; John Flax; Dayan B Goodenowe
Related Documents :
15494618 - Association of hyperhomocysteinemia in alzheimer disease with elevated neopterin levels.
10325448 - Clinical diagnosis of dementia with lewy bodies in a japanese dementia registry.
18525128 - Value of measuring plasmatic levels of neurosin in the diagnosis of alzheimer's disease.
16267638 - Sonographic discrimination of dementia with lewy bodies and parkinson's disease with de...
10347548 - Cytogenetic analysis and ras mutations in primary myelodysplastic syndromes.
9499778 - Terson syndrome. results of vitrectomy and the significance of vitreous hemorrhage in p...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Journal of psychiatry & neuroscience : JPN     Volume:  35     ISSN:  1488-2434     ISO Abbreviation:  J Psychiatry Neurosci     Publication Date:  2010 Jan 
Date Detail:
Created Date:  2009-12-30     Completed Date:  2010-03-01     Revised Date:  2010-09-28    
Medline Journal Info:
Nlm Unique ID:  9107859     Medline TA:  J Psychiatry Neurosci     Country:  Canada    
Other Details:
Languages:  eng     Pagination:  59-62     Citation Subset:  IM    
Affiliation:
Phreedom Pharma, Saskatoon, Sask., Canada. p.wood@phenomenome.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Aged, 80 and over
Alzheimer Disease / blood*,  genetics,  psychology*
Apolipoproteins E / genetics
Chromatography, Liquid
Cognition*
Docosahexaenoic Acids / blood
Female
Humans
Male
Pilot Projects
Plasmalogens / biosynthesis,  blood*
Psychiatric Status Rating Scales
Tandem Mass Spectrometry
Time Factors
Chemical
Reg. No./Substance:
0/Apolipoproteins E; 0/Plasmalogens; 25167-62-8/Docosahexaenoic Acids
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Structural abnormality of the substantia nigra in children with attention-deficit hyperactivity diso...
Next Document:  Symmetrical bilateral Becker melanosis: A rare presentation.